Besides ncRNAs, genes such as TP53 and MDM2 or the expression of DNA repair enzymes like ERCC1 can be used as a prognostic and predictive factor in lung cancer patients to regulate the sensitivity of cisplatin. This evidence concerns the gene MDM2 and lung cancer.